ARS Pharmaceuticals, Inc. — Director's Dealing 2020

Dec 4, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Silverback Therapeutics, Inc. (SBTX)
CIK: 0001671858
Period of Report: 2020-12-03

Reporting Person: Shawver Laura (Director, Chief Executive Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	79213	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock option (right to buy)	$1.27	2030-04-28	Common Stock (481737)		Direct
Stock option (right to buy)	$1.27	2030-04-28	Common Stock (67615)		Direct
Stock option (right to buy)	$1.27	2030-04-28	Common Stock (152238)		Direct
Stock option (right to buy)	$6.65	2030-09-30	Common Stock (222192)		Direct

Footnotes

F1: 25% of the shares shall vest on April 16, 2021 and the remaining shares shall vest in 36 equal monthly installments thereafter.

F2: The shares shall vest in 48 equal monthly installments beginning on August 1, 2020.

F3: The shares shall vest in 48 equal monthly installments beginning on October 18, 2020.

F4: The shares shall vest in 48 equal monthly installments beginning on October 22, 2020.